The Canadian Competition Authority completes preliminary investigation into potential anti-competitive harm from relabelled biologic drugs

Competition Bureau completes preliminary investigation of relabelled biologic drugs* The Competition Bureau has completed its preliminary investigation into potential anti-competitive harm from relabelled biologic drugs. Relabelled biologic drugs are identical to originator biologic drugs but marketed under a secondary brand name.

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Canadian Competition Bureau, The Canadian Competition Authority completes preliminary investigation into potential anti-competitive harm from relabelled biologic drugs, 27 June 2022, e-Competitions August 2022, Art. N° 107465

Visites 63

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues